JV-1-36

Cat. No.:	HY-P3397
CAS No.:	221377-79-3
Molecular Formula:	$C_{172}H_{284}ClN_{53}O_{41}$
Molecular Weight:	3785.88
Sequence:	{N-(2-phenylacetyl)}-Tyr-{d-Arg}-Asp-Ala-Ile-{4-Cl-Phe}-Thr-Asn-{Har}-{Tyr(Me)}-Arg-Lys-Val-Leu-{Abu}-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-{Nle}-{d-Arg}-{Har}-NH2
Sequence Shortening:	{N-(2-phenylacetyl)}-Y-{d-Arg}-DAI-{4-Cl-Phe}-TN-{Har}-{Tyr(Me)}-RKVL-{Abu}-QLSARKLLQDI-{Nle}-{d-Arg}-{Har}-NH2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	JV-1-36 is a growth hormone-releasing hormone (GHRH) antagonist. JV-1-36 inhibits the production of reactive oxygen species in A549 lung cancer cells. JV-1-36 can be used to study the effect of GHRH antagonists in vitro [1].
IC_{50} & Target	IC50: growth hormone-releasing hormone (GHRH)[1].
In Vitro	JV-1-36 (0.01-15 μM; 8 h) reduces cell viability in A549 cells at higher concentrations (5-15 μM), and (2-15 μM; 8 h) also decreases cell viability in Hela cells[1]. JV-1-36 (1 μM; 8 h) significantly reduces the production of ROS induced by H_2O_2 (0.1 mM; 8 h) in A549 lung cancer cells, exerting antioxidant effects[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kubra KT, et al. Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells. Endocrines. 2022 Dec;3(4):813-820.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA